Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts, USA.
Anticancer Agents Med Chem. 2009 Dec;9(10):1123-8. doi: 10.2174/187152009789735071.
Lymphoid malignancies may affect the eye either as primary intraocular lymphomas (PIOL), or by secondary involvement of a nodal lymphoma. PIOL is a subtype of primary central nervous system (CNS) lymphoma and in up to 98% of the cases are non-Hodgkin's B cell lymphomas. PIOL may occur in isolation, without involvement of the CNS. They may affect both the vitreous and the retina, while secondary invasion predominantly affects the uvea. Both forms frequently masquerade as intraocular inflammation or uveitis. Systemic chemotherapy, alone or in combination with radiotherapy has been used in the past for the treatment of PIOL. Methotrexate and rituximab are immunomodulatory agents used in the treatment of cancer and autoimmune diseases. Recent reports have shown the intraocular safety and efficacy of both of these agents for the treatment of PIOL.
淋巴恶性肿瘤可能会影响眼睛，表现为眼内原发性淋巴瘤（PIOL），或者淋巴结淋巴瘤的继发性累及。PIOL 是原发性中枢神经系统（CNS）淋巴瘤的一个亚型，在多达 98%的病例中为非霍奇金氏 B 细胞淋巴瘤。PIOL 可孤立发生，不伴有 CNS 累及。它可影响玻璃体和视网膜，而继发性侵犯主要影响葡萄膜。这两种形式经常伪装为眼内炎症或葡萄膜炎。过去，PIOL 的治疗采用单独化疗或联合放化疗。甲氨蝶呤和利妥昔单抗是用于治疗癌症和自身免疫性疾病的免疫调节药物。最近的报告显示，这两种药物治疗 PIOL 的眼内安全性和有效性。
